Information standards for innovative surgery: what patients need to know
Christin Hoffmann(University Hospitals Bristol NHS Foundation Trust), Malini Mistry, Andrew Thomas(Deakin University), José Miola(University of Leicester), Shelley Potter(At Bristol), Gijs van Boxel, Sian Cousins(University Hospitals Bristol NHS Foundation Trust), Jesmond Zahra, Della Ogunleye, Ben Gibbison(University Hospitals Bristol NHS Foundation Trust), Angus McNair(University of Bristol), Umberto Benedetto(University of Oxford), H Robertson, Hilary Bekker(University of Leeds), Eric Deeson, Simon Mercer, Daniel Leff, David Messenger(University Hospitals Bristol NHS Foundation Trust), Samuel Lawday, Kerry Avery(University of Bristol), Louisa Wickham(Moorfields Eye Hospital NHS Foundation Trust), James Wheeler(Cambridge University Hospitals NHS Foundation Trust), Pete Wheatstone(Macmillan Cancer Support), Natalie Blencowe(NIHR Bristol Biomedical Research Centre), John Mathews, James Hewes, Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Nimish Patel(University of California San Diego), N Carter, Leila Rooshenas(University Hospitals Bristol NHS Foundation Trust), David Jayne(University of Leeds), Jonathan Ives(University Hospitals Bristol NHS Foundation Trust), Abigail Vallance(North Bristol NHS Trust), Gita Giddens, Daisy Elliott(University of Bristol), Hollie Richards, Giles Birchley(At Bristol), Aileen Clarke(University of Oxford), Rhiannon Macefield(University Hospitals Bristol NHS Foundation Trust), Cynthia Ochieng(University Hospitals Bristol NHS Foundation Trust), M. Turner(University of Liverpool), Nairn Wilson(University of London), Efstratios Alexandridis, Adam Toms(Genomics England), A.D. Toms, Barry Main(University Of Bristol Dental Hospital), Joe A. Howell, Alison M. Hutchinson(Barwon Health)
Cited by 4
Related Papers
The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care
|European Journal of Cancer|2005|687
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605